Infant Formula's Safety Reckoning: Nara Organics, Operation Stork Speed and a Pivotal 2026

Infant Formula's Safety Reckoning: Nara Organics, Operation Stork Speed and a Pivotal 2026

Infant formula is one of the most tightly controlled consumer products in the United States.

It can serve as an infant's entire source of nutrition during a period of extremely rapid growth. A manufacturing error, nutritional imbalance or microbiological failure can therefore affect a population with very little physiological margin for error.

In 2026, three developments placed that safety system under unusually intense scrutiny:

A nationwide recall of Nara Organics Whole Milk Organic Powdered Infant Formula during a multistate infant-botulism investigation

Continued implementation of the FDA's Operation Stork Speed, including the first comprehensive review of infant-formula nutrient requirements in decades and expanded contaminant surveillance

The entrance of Little Spoon with unusually public batch-testing thresholds, including a voluntary microbiological indicator limit it describes as ten times stricter than international guidance

These events did not form a simple chain in which one directly caused the next.

Operation Stork Speed began in March 2025, before the Nara incident. Little Spoon announced its formula and testing programme in March 2026, also before the Nara recall in June.

But together they reveal a category approaching an important inflection point:

Infant-formula safety is moving from basic regulatory compliance toward greater surveillance, more public testing data and competition over who can demonstrate the strictest controls.

This is one signal from the Consensys Innovation Signals Engine, which continuously scans a library of more than one million products worldwide for emerging shifts in formulation, positioning and consumer demand.

Signal: Safety Standards Becoming a Competitive Territory

The Nara recall began with an epidemiological signal—not a positive formula test

On June 12, 2026, the FDA contacted Nara Organics after FDA and CDC investigators identified a multistate cluster of infant-botulism cases associated with the company's formula.

The following day, Nara agreed to recall all Nara Organics Whole Milk Organic Powdered Infant Formula currently on the US market. The recall covered all lots and both the 400-gram and 700-gram formats.

The product had been sold:

At Target stores nationwide

Through Target.com

Directly through Nara.com

From approximately July 2025 through June 2026

The formula was manufactured in Europe for exclusive sale in the United States.

Brand: Nara Organics

Product: Whole Milk Organic Powdered Infant Formula

Recall Date: June 13, 2026

Recall Scope: All product currently in the US market

Investigation Type: Multistate infant-botulism investigation

The formula had not tested positive for botulism bacteria

This distinction is essential.

At the time of the recall announcement, Nara stated that its formula had not tested positive for Clostridium botulinum.

The FDA nevertheless recommended a complete recall because of:

The severity of infant botulism

The pattern connecting the affected infants

Their reported consumption of Nara formula

The need to act before laboratory testing was complete

Three identified infants in California, Pennsylvania and Washington had been hospitalised after consuming the product. Later FDA reporting referenced an additional case under investigation, bringing the known cluster to four infants.

Evidence Signal: Strong Epidemiological Association

Evidence Gap: Product Contamination Not Yet Confirmed

The responsible wording is therefore:

Nara formula was associated with an infant-botulism investigation and recalled as a precaution; the product had not yet tested positive for C. botulinum.

It should not be described as a confirmed contaminated formula unless later laboratory results establish that fact.

Infant botulism is different from ordinary food poisoning

Infant botulism generally occurs when a baby ingests spores of Clostridium botulinum.

The spores can germinate in the immature intestinal environment and produce a neurotoxin inside the body.

Symptoms may include:

Constipation

Poor feeding

Weak cry

Drooping eyelids

Reduced facial expression

Generalised weakness

Poor head control

Difficulty swallowing

Breathing problems

The condition can progress to paralysis and respiratory failure, requiring hospitalisation and specialised treatment.

Health Risk: Neurotoxin Produced Inside the Infant Gut

This makes the presence of spores especially important even when the powdered product itself does not contain preformed toxin.

Powdered infant formula is not sterile

Powdered infant formula is manufactured under strict controls, but it is not generally considered sterile.

That creates a different risk profile from ready-to-feed liquid formula.

Potential contamination may arise through:

Raw ingredients

Environmental spores

Post-heat-treatment handling

Drying systems

Filling equipment

Packaging environments

Household preparation

The safety system must therefore combine manufacturing controls with preparation guidance and rapid investigation of any illness cluster.

Risk Signal: Low-Frequency Organism, High-Consequence Population

The Nara investigation followed a much larger ByHeart outbreak

The 2026 Nara case did not emerge in isolation.

Beginning in late 2025, the FDA and CDC investigated a much larger infant-botulism outbreak associated with ByHeart Whole Nutrition Infant Formula.

FDA testing later identified C. botulinum toxin Type A in a closed product sample, and genomic analysis connected that sample with clinical isolates and organic whole-milk-powder ingredients used in production.

The ByHeart outbreak resulted in a nationwide recall and hospitalisation of numerous infants across multiple states.

Nara then became the second formula-associated infant-botulism investigation identified within a relatively short period.

Market Signal: Repeated Spore-Forming Bacteria Scrutiny

This sequence increased attention on a risk that had historically received less public discussion than:

Cronobacter

Salmonella

Heavy metals

Nutrient deficiencies

Foreign material

Operation Stork Speed started before both 2026 developments

The original database row suggests that the Nara outbreak triggered the FDA's regulatory overhaul.

That chronology is incorrect.

The US Department of Health and Human Services and FDA announced Operation Stork Speed on March 18, 2025.

The initiative included actions intended to:

Review infant-formula nutrient requirements

Increase testing for heavy metals and other contaminants

Improve transparency around formula ingredients

Encourage development of new products

strengthen scientific and regulatory infrastructure

Improve the reliability and resilience of formula supply

Evidence Correction: Regulatory Review Predated the Nara Recall

The Nara case may intensify the importance of the programme.

It did not initiate it.

The nutrient review is the first comprehensive one in decades

US infant-formula regulations specify minimum and, for some nutrients, maximum quantities required in formula.

The modern framework was largely established decades ago, and Operation Stork Speed opened the first comprehensive review of these nutrient requirements since the late 1990s.

The review considers scientific developments involving nutrients such as:

Iron

Vitamin D

Choline

DHA and other fatty acids

Protein

Micronutrients

Potential upper and lower limits

An FDA expert-panel process has evaluated four decades of accumulated research to advise how the nutrient framework might be modernised.

Innovation Type: Evidence-Based Nutrient Standard Modernisation

This review is not only about preventing contamination.

It asks whether the nutritional composition required by law still reflects current science.

Operation Stork Speed is broader than a nutrient rule

The programme should not be described solely as an attempt to write one new nutrient-standard rule.

FDA materials describe a wider set of actions covering:

Nutrient requirements

Contaminant surveillance

Microbiological risks

Formula ingredients

Labelling transparency

Product innovation

Supply resilience

In 2026, the FDA said it would begin implementing a plan to modernise nutrient requirements based on scientific evidence, expert input and public recommendations.

The agency also increased testing for spore-forming microbiological contaminants, specifically including Clostridium botulinum and Bacillus cereus, to inform future risk-reduction strategies.

Regulatory Signal: Safety Review Expanding Beyond Traditional Pathogens

FDA conducted its largest-ever formula contaminant survey

In April 2026, the FDA released results from what it described as its largest-ever testing effort for contaminants in infant formula marketed in the United States.

The work examined substances including:

Arsenic

Lead

Cadmium

Mercury

PFAS

Other environmental contaminants

The FDA said it would continue surveillance and test formulas that entered the market after the initial survey began.

Innovation Type: Category-Wide Regulatory Surveillance

This shifts the regulatory model from responding only to individual incidents toward collecting comparative data across the whole market.

Little Spoon entered formula with testing as the main brand proposition

In March 2026, baby-food company Little Spoon launched an organic whole-milk infant formula.

The product is manufactured through an experienced international partner and sold with a transparency system that the company says includes:

More than 2,000 manufacturing quality and safety checks per batch

Third-party finished-product testing

Screening for more than 500 contaminants and toxins

Published batch-level results

A public list of internal testing thresholds

Voluntary testing for spore-forming bacterial indicators

Brand: Little Spoon

Product: Organic Whole Milk Infant Formula

Market Entry: March 2026

Trust Mechanism: Public batch-level safety thresholds

Innovation Type: Safety Transparency as Product Differentiation

Instead of treating quality control as invisible factory infrastructure, Little Spoon turns it into consumer-facing content.

The "ten times stricter" claim refers to SRC

Little Spoon voluntarily tests for Sulfite-Reducing Clostridia, abbreviated SRC.

SRC is a broader group of anaerobic, spore-forming bacteria used as a microbiological hygiene or process indicator.

The company describes an international guidance level of:

100 colony-forming units per gram

Little Spoon says it applies an internal limit of:

10 colony-forming units per gram

That is the basis for its "ten times stricter" claim.

Evidence Signal: Publicly Quantified Internal Threshold

SRC is not the same thing as Clostridium botulinum

This is the most important limitation of the Little Spoon claim.

Sulfite-reducing clostridia include a broader group of organisms.

Testing for SRC can help indicate:

Spore-forming bacterial load

Ingredient or process hygiene

Environmental control

Conditions that could warrant further investigation

But a low SRC count does not automatically prove:

No C. botulinum spores are present

No botulism risk exists

Every individual unit is sterile

The test directly measures toxin production

Evidence Correction: Indicator Testing, Not Direct Botulism Certification

Little Spoon's threshold may represent a meaningful additional control.

It should not be described as testing directly for botulism at a limit ten times stricter than law.

The company is going beyond a requirement that does not yet exist

Little Spoon says US regulators do not currently require routine SRC testing at the threshold it applies.

That gives the company a distinctive claim:

We monitor an additional microbiological indicator and publish the limit we use.

This differs from saying:

The FDA requires 100 CFU/g and we require 10 CFU/g.

The 100 CFU/g figure is presented as an international guidance reference, not a universal US legal maximum for every finished formula.

Trust Signal: Voluntary Standard Above Regulatory Minimum

Risk Signal: Consumer May Confuse Internal Standard With Law

"Stricter" does not automatically mean clinically safer

A lower numerical limit appears intuitively better.

But the public evidence reviewed does not establish that a 10 CFU/g SRC threshold produces a tenfold reduction in infant-botulism risk compared with 100 CFU/g.

To demonstrate that, researchers would need evidence connecting:

SRC levels

Specific C. botulinum contamination

Finished-product exposure

Infant illness incidence

Manufacturing environments

Ingredient sources

Evidence Gap: Indicator Threshold Not Directly Linked to Tenfold Risk Reduction

The correct conclusion is:

Little Spoon uses a numerical internal control that is ten times lower than the referenced guidance level—not that the formula is proven ten times safer.

Public certificates of analysis could change formula marketing

Most parents cannot see what happens inside an infant-formula factory.

They usually rely on:

Brand reputation

FDA market authorisation

Organic certification

Ingredient lists

Pediatrician recommendation

Retailer availability

Publishing batch-level results adds another trust mechanism.

A parent may be able to inspect testing for:

Heavy metals

Microbiological indicators

Pesticide residues

Environmental contaminants

Nutritional composition

Innovation Territory: Lot-Level Formula Transparency

This converts quality assurance from a hidden internal process into a searchable consumer asset.

Transparency still depends on how the data are presented

A certificate of analysis can create reassurance without genuine understanding.

Parents may not know:

Whether the sample represented the full batch

Which laboratory performed the test

Whether the method was validated

What the detection limit was

Whether the result applies through shelf life

Which hazards were not tested

Whether the laboratory is financially independent

Risk Signal: Testing Volume Becoming Trust Theatre

The number of tests is less important than:

Test relevance

Sampling design

Method quality

Action thresholds

Corrective procedures

Public accessibility

Nara and Little Spoon illustrate two different evidence systems

The Nara recall was driven primarily by epidemiology.

Investigators identified infants with the same rare condition and a common product exposure.

Little Spoon's proposition is built around preventive product testing.

These systems answer different questions.

Epidemiological surveillance

Question: Are unusual illnesses appearing among people who consumed the same product?

Batch microbiological testing

Question: Does the sampled formula meet predefined laboratory limits before release?

Environmental monitoring

Question: Are organisms present in the manufacturing environment?

Ingredient testing

Question: Do incoming ingredients carry unacceptable contamination?

Innovation Territory: Multi-Layer Microbiological Assurance

No single layer can guarantee zero risk.

The strongest safety system combines all of them.

A negative product test does not always close an outbreak investigation

Microbial contamination can be:

Rare

Unevenly distributed

Present in only a small number of units

Difficult to detect in retained samples

Introduced through one ingredient lot

Lost during sampling

A negative result from a limited number of samples does not always exclude contamination somewhere within a large production run.

That is why regulators consider epidemiological evidence alongside laboratory testing.

Evidence Principle: Absence in the Sample Is Not Proof of Absence in Every Unit

This helps explain why FDA could recommend recalling Nara formula before obtaining a positive product result.

A positive indicator test also requires interpretation

SRC testing presents the reverse problem.

Detecting a broader indicator organism does not automatically establish the presence of C. botulinum.

The result may instead signal:

A need for follow-up testing

Ingredient-quality concern

Process-control weakness

Elevated spore load

Potential environmental issue

Evidence Principle: Indicator Organism Is a Warning Signal, Not the Final Diagnosis

Both positive and negative findings require context.

The category is moving toward hazard prevention rather than outbreak response

Historically, public attention to formula safety often follows a crisis.

A product is recalled.

A plant closes.

Parents search for alternatives.

Supply becomes strained.

The 2026 developments point toward a more preventive model:

FDA collects market-wide surveillance data.

Nutrient standards are reviewed before obvious deficiency emerges.

Manufacturers monitor additional spore-forming organisms.

Brands publish internal thresholds.

Ingredient and environmental risks receive more scrutiny.

Market Signal: From Minimum Compliance to Demonstrable Prevention

Voluntary testing can place pressure on competitors

When one brand publishes exact thresholds, it changes the competitive conversation.

Parents may begin asking other manufacturers:

Do you test for SRC?

What limit do you use?

Do you test every batch?

Can I see the results?

Which laboratory performs the work?

Do you test ingredients as well as finished formula?

What happens when a result approaches the limit?

Competitive Signal: Transparency Raises the Category Baseline

A voluntary standard can become commercially mandatory before it becomes legally mandatory.

Mandatory adoption would require a validated scientific basis

The original research recommendation asks whether Little Spoon's stricter testing should become compulsory.

That cannot be answered solely by comparing 10 CFU/g with 100 CFU/g.

Regulators would need to determine:

Whether SRC is the correct indicator

Which analytical method should be standardised

Appropriate sample size and frequency

Whether ingredients and finished formula need separate limits

What threshold predicts meaningful risk

Required corrective action after detection

Cost and laboratory capacity

Whether direct C. botulinum testing is technically practical

Regulatory Question: What Test Best Predicts Real-World Harm?

A rule should be stricter where evidence supports it—not merely because a smaller number sounds safer.

Formula safety now extends beyond the final powder

The investigations highlight the need to control the complete production chain:

Dairy and other agricultural inputs

Vitamin and mineral premixes

Organic whole-milk powder

Supplier facilities

Transport

Formula manufacturing

Dry blending

Filling and packaging

Warehousing

Consumer preparation

The ByHeart investigation specifically connected product and clinical isolates with an organic whole-milk-powder ingredient, showing how an upstream component can become central to the finished-product investigation.

Supply-Chain Signal: Ingredient-Level Microbiological Traceability

Europe-made does not automatically mean safer

Nara promoted its formula as manufactured in Germany and meeting both European and US standards.

Its European production history formed part of the brand's trust proposition.

But geographical origin is not a substitute for:

Batch testing

Ingredient controls

Environmental monitoring

Traceability

Adverse-event surveillance

Risk Signal: Regulatory-Origin Halo

"Made in Europe" may reassure US parents.

It does not eliminate microbiological risk.

Organic certification answers a different question

Both Nara and Little Spoon emphasise organic positioning.

Organic certification addresses defined agricultural and production practices.

It does not certify that a powdered formula is free from:

C. botulinum

Cronobacter

Salmonella

Other spore-forming bacteria

Trust Distinction: Organic Production Versus Microbiological Safety

A formula can meet organic requirements and still require rigorous pathogen controls.

The nutrient and microbiological debates are converging

Operation Stork Speed joins two safety dimensions that are often discussed separately.

Nutritional adequacy

Does the formula provide the required nutrients in suitable amounts?

Microbiological safety

Is the formula manufactured and handled to minimise dangerous organisms?

A formula must succeed at both.

A microbiologically clean product with an incorrect nutrient profile is unsafe.

A nutritionally complete product contaminated with a dangerous pathogen is also unsafe.

Innovation Territory: Integrated Formula Safety Standard

The category's future may involve more public thresholds

Infant-formula labels currently tell parents relatively little about the manufacturer's internal safety system.

Future brands may publish:

Microbiological action limits

Heavy-metal thresholds

Ingredient supplier standards

Environmental-monitoring frequency

Batch-release criteria

Nutrient-retention tolerances

Laboratory accreditation

Recall and traceability performance

Market Signal: Safety Data Becoming a Consumer Product Feature

This would make formula marketing look less like ordinary packaged food and more like pharmaceutical-quality communication.

But parents should not have to become microbiologists

Radical transparency can create information overload.

Most caregivers cannot reasonably evaluate:

CFU per gram

Spore-forming indicator organisms

Analytical detection limits

Sampling confidence

Genomic sequencing

Environmental-monitoring zones

Regulators and healthcare professionals still need to translate technical results into simple decisions.

Consumer Need: Clear Action, Not Only More Data

The ideal system provides both:

Full technical evidence for experts

Clear, accurate guidance for parents

2026 is an inflection point—but the change began earlier

The strongest version of the story is not that one Nara recall suddenly transformed US infant-formula regulation.

It is that several pressures converged:

The legacy of the 2022 formula crisis

Operation Stork Speed beginning in 2025

The ByHeart botulism outbreak in late 2025

Expanded FDA contaminant testing in early 2026

Little Spoon's public safety-threshold strategy in March 2026

The Nara recall in June 2026

Increased FDA attention to spore-forming microbiological hazards

Evidence Correction: Converging Developments, Not One Direct Causal Chain

The real competitive advantage may become provable control

Formula brands traditionally compete through:

Ingredient quality

Breast-milk comparisons

Organic status

Digestive comfort

Whole-milk positioning

HMOs

DHA

European sourcing

The next competitive frontier may be:

Exact safety thresholds

Accessible batch results

Ingredient-level traceability

Environmental monitoring

Faster adverse-event response

Independent verification

Signal: Safety Proof Becoming Brand Equity

A stricter voluntary standard can expose the weakness of minimum compliance

When a company publicly adopts a lower threshold than industry guidance, it raises a difficult question:

If the stricter level is technically achievable and scientifically useful, why is it not required for everyone?

But the reverse question is equally important:

If the lower threshold has not been shown to predict lower illness risk, is the number mainly a marketing device?

The answer requires independent scientific evaluation.

Evidence Gap: Commercial Threshold Needs Public-Health Validation

Formula safety cannot be communicated through one badge

The strongest future trust system will combine:

1. Regulatory oversight

Clear mandatory standards and effective inspections.

2. Preventive manufacturing controls

Ingredient, environment and finished-product testing.

3. Epidemiological surveillance

Rapid detection of rare illness patterns.

4. Public transparency

Accessible thresholds and batch-level results.

5. Clinical guidance

Clear instructions for parents and healthcare providers.

Innovation Territory: Five-Layer Formula Assurance

The category has entered a higher-accountability era

The Nara recall demonstrated that regulators may act decisively on a severe epidemiological signal before laboratory confirmation is available.

Operation Stork Speed demonstrates that FDA is willing to revisit foundational nutrient and contaminant standards.

Little Spoon demonstrates that testing protocols can become part of the visible consumer proposition rather than remaining a trade secret.

None of these developments alone proves that infant formula is becoming unsafe.

Together, they show that old assumptions are being challenged.

The emerging standard is no longer simply:

Does the product comply with today's minimum rules?

It is becoming:

After the Nara Organics recall, can the manufacturer show, batch by batch and hazard by hazard, why parents should trust it?

Brand Radar Signal Tags

Brands and Organisations

Nara Organics Little Spoon ByHeart U.S. Food and Drug Administration Centers for Disease Control and Prevention Department of Health and Human Services Target National Institutes of Health

Products

Nara Organics Whole Milk Organic Powdered Infant Formula Little Spoon Organic Whole Milk Infant Formula ByHeart Whole Nutrition Infant Formula

Regulatory Programmes

Operation Stork Speed Infant Formula Nutrient Review FDA Market-Wide Formula Testing Nutrition Regulatory Science Program Closer to Zero Microbiological Contaminant Surveillance

Microbiological Signals

Clostridium botulinum Infant Botulism Sulfite-Reducing Clostridia SRC Bacillus cereus Cronobacter Salmonella Spore-Forming Bacteria Environmental Monitoring

Testing Claims

10 CFU/g Internal SRC Limit 100 CFU/g Referenced International Guidance Tenfold Lower Numerical Threshold More Than 2,000 Safety Checks More Than 500 Contaminants and Toxins Third-Party Batch Testing Published Batch Results

Innovation Types

Safety Transparency as Product Differentiation Lot-Level Formula Transparency Indicator-Organism Monitoring Category-Wide Regulatory Surveillance Nutrient Standard Modernisation Multi-Layer Microbiological Assurance Integrated Formula Safety Standard Five-Layer Formula Assurance

Evidence Signals

Multistate Epidemiological Cluster All Nara Lots Recalled Nara Product Not Yet Positive for C. botulinum ByHeart Product Sample Previously Positive Operation Stork Speed Began in March 2025 Little Spoon Claim Based on SRC Indicator Exact Internal Threshold Publicly Disclosed

Risk Signals

Indicator Test Mistaken for Direct Pathogen Test Tenfold Lower Limit Mistaken for Tenfold Safer Negative Sample Mistaken for Zero Risk Organic Certification Mistaken for Microbial Safety European-Manufacturing Halo Testing Volume Without Methodological Context Powdered Formula Is Not Sterile Rare Contamination With Severe Consequences

Market Signals

Safety Proof Becoming Brand Equity Voluntary Standard Raising Competitive Baseline Public Certificates of Analysis Ingredient-Level Traceability Formula Safety Inflection Point From Minimum Compliance to Demonstrable Prevention

Sources

Nara Organics recall and outbreak investigation

FDA — Outbreak Investigation of Infant Botulism: Powdered Infant Formula: Confirms the multistate investigation, FDA's June 12 recall recommendation, the June 13 recall and European manufacture of Nara formula. https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-infant-botulism-powdered-infant-formula-june-2026

FDA — Nara Organics Recall Notice: Confirms all product was recalled and states that Nara formula had not tested positive for C. botulinum at the time of announcement. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/nara-organics-recalls-all-lots-nara-infant-formula-because-possible-health-risk

FDA — Infant Formulas Marketed in the US: Lists Nara's recall status and advises consumers not to use the product.

Associated Press: Reports the original three hospitalised infants, the nationwide recall and product distribution through Target and Nara.com. https://www.insurancejournal.com/news/national/2026/06/22/874594.htm

Reuters: Confirms the precautionary nationwide recall and that no positive product test had yet been announced.

Earlier ByHeart outbreak

FDA — ByHeart Infant Botulism Investigation: Reports positive C. botulinum toxin Type A findings in a closed product sample and links with clinical and organic whole-milk-powder isolates.

Operation Stork Speed

FDA/HHS — Operation Stork Speed Announcement: Establishes that the initiative began in March 2025 and covers nutrient review, contaminant testing, transparency and formula innovation.

FDA — Comprehensive Nutrient Review: Describes the first broad review of infant-formula nutrient requirements in decades.

FDA — Operation Stork Speed Programme Page: Provides the current programme structure and research activities.

FDA — 2026 Human Foods Programme Deliverables: States that FDA will begin implementing a plan to modernise formula nutrient requirements during 2026.

FDA — Manufacturer Information: Confirms increased attention to spore-forming contaminants including C. botulinum and B. cereus.

American Society for Nutrition expert-panel review: Explains the scientific review of nutrient standards developed through Operation Stork Speed.

FDA contaminant testing

FDA — Largest-Ever Infant Formula Testing Survey: Reports expanded market-wide formula testing and plans for continued surveillance.

FDA — Heavy-Metal Testing Results: Connects the 2026 testing programme with Operation Stork Speed and Closer to Zero.

FDA — PFAS in Infant Formula: Reports testing for 30 PFAS and future plans for additional surveillance.

Little Spoon testing programme

Little Spoon — Organic Whole Milk Infant Formula: Describes third-party testing, more than 2,000 safety checks and its public testing system.

Little Spoon — Botulism and Formula Guide: Provides the company's explanation of spores, botulism and its approach to testing.

FoodNavigator-USA: Reports the 10 CFU/g Little Spoon SRC limit and the referenced 100 CFU/g international guidance level.

Little Spoon launch announcement: States that SRC testing is voluntary and describes the internal threshold as ten times more stringent than international guidance.

Nutrition Insight: Reports batch-level disclosure, testing across more than 500 contaminants and the company's safety positioning.